SNP285C reduces the binding strength between the Sp1 transcription factor and the MDM2 promoter, and is associated with a significantly reduced risk of spontaneous breast, endometrial and ovarian cancer as well as a reduced risk of ovarian cancer among BRCA1 mutation carriers [13-15]. Here, SP1 is linked to ovarian cancer.